Cyclosporine 0.1% (Ikervis(®)) as a corticoid-sparing agent in Lyell syndrome with KeraKlear(®) keratoprosthesis

Cyclosporine 0.1% was used in a patient with Lyell syndrome, which had undergone a KeraKlear(®) keratoprosthesis implant due to the severe ocular involvement to avoid overuse of corticoid agents. To the best of our knowledge, this is the first reported case of cyclosporine 0.1% eye drops to use in L...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahhal-Ortuño, Miriam, Fernández-Santodomingo, Alex-Samir, Villena-Alvarado, Carla, Marín-Payá, Emma, Aguilar-González, Marina, García-Delpech, Salvador
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787086/
https://www.ncbi.nlm.nih.gov/pubmed/33437608
http://dx.doi.org/10.4103/tjo.tjo_1_20
_version_ 1783632758227075072
author Rahhal-Ortuño, Miriam
Fernández-Santodomingo, Alex-Samir
Villena-Alvarado, Carla
Marín-Payá, Emma
Aguilar-González, Marina
García-Delpech, Salvador
author_facet Rahhal-Ortuño, Miriam
Fernández-Santodomingo, Alex-Samir
Villena-Alvarado, Carla
Marín-Payá, Emma
Aguilar-González, Marina
García-Delpech, Salvador
author_sort Rahhal-Ortuño, Miriam
collection PubMed
description Cyclosporine 0.1% was used in a patient with Lyell syndrome, which had undergone a KeraKlear(®) keratoprosthesis implant due to the severe ocular involvement to avoid overuse of corticoid agents. To the best of our knowledge, this is the first reported case of cyclosporine 0.1% eye drops to use in Lyell syndrome previously treated with keratoprosthesis implant.
format Online
Article
Text
id pubmed-7787086
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-77870862021-01-11 Cyclosporine 0.1% (Ikervis(®)) as a corticoid-sparing agent in Lyell syndrome with KeraKlear(®) keratoprosthesis Rahhal-Ortuño, Miriam Fernández-Santodomingo, Alex-Samir Villena-Alvarado, Carla Marín-Payá, Emma Aguilar-González, Marina García-Delpech, Salvador Taiwan J Ophthalmol Case Report Cyclosporine 0.1% was used in a patient with Lyell syndrome, which had undergone a KeraKlear(®) keratoprosthesis implant due to the severe ocular involvement to avoid overuse of corticoid agents. To the best of our knowledge, this is the first reported case of cyclosporine 0.1% eye drops to use in Lyell syndrome previously treated with keratoprosthesis implant. Wolters Kluwer - Medknow 2020-04-21 /pmc/articles/PMC7787086/ /pubmed/33437608 http://dx.doi.org/10.4103/tjo.tjo_1_20 Text en Copyright: © 2020 Taiwan J Ophthalmol http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Case Report
Rahhal-Ortuño, Miriam
Fernández-Santodomingo, Alex-Samir
Villena-Alvarado, Carla
Marín-Payá, Emma
Aguilar-González, Marina
García-Delpech, Salvador
Cyclosporine 0.1% (Ikervis(®)) as a corticoid-sparing agent in Lyell syndrome with KeraKlear(®) keratoprosthesis
title Cyclosporine 0.1% (Ikervis(®)) as a corticoid-sparing agent in Lyell syndrome with KeraKlear(®) keratoprosthesis
title_full Cyclosporine 0.1% (Ikervis(®)) as a corticoid-sparing agent in Lyell syndrome with KeraKlear(®) keratoprosthesis
title_fullStr Cyclosporine 0.1% (Ikervis(®)) as a corticoid-sparing agent in Lyell syndrome with KeraKlear(®) keratoprosthesis
title_full_unstemmed Cyclosporine 0.1% (Ikervis(®)) as a corticoid-sparing agent in Lyell syndrome with KeraKlear(®) keratoprosthesis
title_short Cyclosporine 0.1% (Ikervis(®)) as a corticoid-sparing agent in Lyell syndrome with KeraKlear(®) keratoprosthesis
title_sort cyclosporine 0.1% (ikervis(®)) as a corticoid-sparing agent in lyell syndrome with keraklear(®) keratoprosthesis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787086/
https://www.ncbi.nlm.nih.gov/pubmed/33437608
http://dx.doi.org/10.4103/tjo.tjo_1_20
work_keys_str_mv AT rahhalortunomiriam cyclosporine01ikervisasacorticoidsparingagentinlyellsyndromewithkeraklearkeratoprosthesis
AT fernandezsantodomingoalexsamir cyclosporine01ikervisasacorticoidsparingagentinlyellsyndromewithkeraklearkeratoprosthesis
AT villenaalvaradocarla cyclosporine01ikervisasacorticoidsparingagentinlyellsyndromewithkeraklearkeratoprosthesis
AT marinpayaemma cyclosporine01ikervisasacorticoidsparingagentinlyellsyndromewithkeraklearkeratoprosthesis
AT aguilargonzalezmarina cyclosporine01ikervisasacorticoidsparingagentinlyellsyndromewithkeraklearkeratoprosthesis
AT garciadelpechsalvador cyclosporine01ikervisasacorticoidsparingagentinlyellsyndromewithkeraklearkeratoprosthesis

Ejemplares similares